Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.

Pelacarsen cut lipoprotein(a) by 78.4% at 12 months but did not reduce MACE vs placebo in 8322 patients with cardiovascular disease (HR, 1.02).

Despite lowering free IL-6 and hsCRP, monthly ziltivekimab did not reduce 3-point MACE vs placebo in 6376 patients with ASCVD and CKD.

In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.

Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.

Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.

Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.

Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.